

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS? ### Status: Signing onto Dialog \*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Login successfulDialog level 05.20.01D

Last logoff: 21dec07 14:10:24

Logon file405 23jan08 10:56:52

\*\*\* ANNOUNCEMENTS \*\*\*

\*\*\*

\*\*\*The 2008 EMTREE Thesaurus has been added to EMBASE (Files 72, 73, 772, and 972)

NEW FILES RELEASED

\*\*\*Trademarkscan - South Korea (File 655)

RESUMED UPDATING

\*\*\*File 154 & F155, MEDLINE

\*\*\*File 156, ToxFile

\*\*\*

RELOADS COMPLETED

\*\*\*Files 72 & 73, EMBASE

\*\*\*Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

\*\*\*

NEWS

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

\*\*\*

>>>For the latest news about Dialog products, services, content<<<

>>>and events, please visit What's New from Dialog at <<<

>>><http://www.dialog.com/whatsnew/>. You can find news about<<<

>>>a specific database by entering HELP NEWS <file number>.<<<

\* \* \*

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.8.0 term=ASCII

\*\*\* DIALOG HOMEBASE(SM) Main Menu \*\*\*

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help                      /L = Logoff                      /NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

?

Terminal set to DLINK

\*\*\* DIALOG HOMEBASE(SM) Main Menu \*\*\*

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help                      /L = Logoff                      /NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

? b biosci

```
>>>          44 is unauthorized
>>>          76 is unauthorized
>>>2 of the specified files are not available
      23jan08 10:57:01 User276653 Session D136.1
          $0.00      0.267 DialUnits FileHomeBase
$0.00 Estimated cost FileHomeBase
$0.03 TELNET
$0.03 Estimated cost this search
$0.03 Estimated total session cost      0.267 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

```
File   5:Biosis Previews(R) 1926-2008/Jan W3
      (c) 2008 The Thomson Corporation
File  24:CSA Life Sciences Abstracts 1966-2007/Aug
      (c) 2007 CSA.
File  28:Oceanic Abstracts 1966-2007/Oct
      (c) 2007 CSA.
File  34:SciSearch(R) Cited Ref Sci 1990-2008/Jan W2
      (c) 2008 The Thomson Corp
File  35:Dissertation Abs Online 1861-2007/Oct
      (c) 2007 ProQuest Info&Learning
File  40:Enviroline(R) 1975-2008/Jan
      (c) 2008 Congressional Information Service
```

File 41:Pollution Abstracts 1966-2007/Sep  
(c) 2007 CSA.

File 45:EMCare 2008/Jan W2  
(c) 2008 Elsevier B.V.

File 50:CAB Abstracts 1972-2008/Dec  
(c) 2008 CAB International

File 65:Inside Conferences 1993-2008/Jan 21  
(c) 2008 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2008/Jan W3  
(c) 2008 Elsevier B.V.

File 73:EMBASE 1974-2008/Jan 23  
(c) 2008 Elsevier B.V.

**\*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see  
HELP NEWS 72 for details.**

File 91:MANTIS(TM) 1880-2007/Apr  
2001 (c) Action Potential

**\*File 91: This database has stopped updating temporarily. Please see  
HELP NEWS 91 for details.**

File 98:General Sci Abs 1984-2007/Dec  
(c) 2007 The HW Wilson Co.

File 110:WasteInfo 1974-2002/Jul  
(c) 2002 AEA Techn Env.

**\*File 110: This file is closed (no updates)**

File 135:NewsRx Weekly Reports 1995-2008/Jan W2  
(c) 2008 NewsRx

File 136:BioEngineering Abstracts 1966-2007/Jan  
(c) 2007 CSA.

File 143:Biol. & Agric. Index 1983-2008/Dec  
(c) 2008 The HW Wilson Co

File 144:Pascal 1973-2008/Jan W2  
(c) 2008 INIST/CNRS

File 155:MEDLINE(R) 1950-2008/Jan 21  
(c) format only 2008 Dialog

**\*File 155: MEDLINE has resumed updating. Please see HELP NEWS 154  
for details.**

File 164:Allied & Complementary Medicine 1984-2008/Jan  
(c) 2008 BLHCIS

File 172:EMBASE Alert 2008/Jan 01  
(c) 2008 Elsevier B.V.

File 185:Zoological Record Online(R) 1864-2008/Feb  
(c) 2008 The Thomson Corp.

**\*File 185: The file has been reloaded to add archive records back to  
1864. Accession numbers have changed.**

File 357:Derwent Biotech Res. \_1982-2008/Dec W4  
(c) 2008 The Thomson Corp.

File 369:New Scientist 1994-2007/Sep W4  
(c) 2007 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3  
(c) 1999 AAAS

**\*File 370: This file is closed (no updates). Use File 47 for more current  
information.**

File 391:Beilstein Database - Reactions 2007/Q3  
(c) 2007 Beilstein GmbH

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 2006 The Thomson Corp

File 467:ExtraMED(tm) 2000/Dec  
(c) 2001 Informania Ltd.

| Set                               | Items              | Description                       |
|-----------------------------------|--------------------|-----------------------------------|
| ? s                               | fibronectin        |                                   |
| S1                                | 160304             | FIBRONECTIN                       |
| ? s s1 and precipitat?            |                    |                                   |
|                                   | 160304             | S1                                |
|                                   | 725879             | PRECIPITAT?                       |
| S2                                | 1379               | S1 AND PRECIPITAT?                |
| ? s s2 and factor                 |                    |                                   |
|                                   | 1379               | S2                                |
|                                   | 6388201            | FACTOR                            |
| S3                                | 327                | S2 AND FACTOR                     |
| ? s s2 and bovine(n)blood(n)serum |                    |                                   |
| Processing                        |                    |                                   |
| Processed                         | 20 of 29 files ... |                                   |
| Completed processing all files    |                    |                                   |
|                                   | 1379               | S2                                |
|                                   | 987825             | BOVINE                            |
|                                   | 9978439            | BLOOD                             |
|                                   | 3250973            | SERUM                             |
|                                   | 342                | BOVINE (N) BLOOD (N) SERUM        |
| S4                                | 2                  | S2 AND BOVINE (N) BLOOD (N) SERUM |
| ? t s4/9,k/1-2                    |                    |                                   |

**4/9,K/1 (Item 1 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2008 The Thomson Corporation. All rts. reserv.

07313370 BIOSIS NO.: 198478048777

**A SIMPLE AND EFFECTIVE ADDITIONAL STEP IN PURIFICATION OF BOVINE BLOOD SERUM FIBRONECTIN**

AUTHOR: ZYKOVA T A (Reprint); ZLATOPOL'SKII A D; MAZUROV V I  
AUTHOR ADDRESS: INST BIOL MED CHEM, ACAD MED SCI USSR, MOSCOW, USSR\*\*USSR  
JOURNAL: Voprosy Meditsinskoi Khimii 25 (5): p114-117 1983  
ISSN: 0042-8809  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: RUSSIAN

ABSTRACT: Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained Ig and other proteins, concentration of which constituted 48 .+-. 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained < 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

REGISTRY NUMBERS: 7783-20-2: AMMONIUM SULFATE  
DESCRIPTORS: AMMONIUM SULFATE IMMUNO GLOBULIN/  
DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics--Transport and Circulation

BIOSYSTEMATIC NAMES: Bovidae--Artiodactyla, Mammalia, Vertebrata,  
Chordata, Animalia

COMMON TAXONOMIC TERMS: Animals; Artiodactyls; Chordates; Mammals;  
Nonhuman Vertebrates; Nonhuman Mammals; Vertebrates

CHEMICALS & BIOCHEMICALS: AMMONIUM SULFATE

CONCEPT CODES:

10054 Biochemistry methods - Proteins, peptides and amino acids  
10058 Biochemistry methods - Carbohydrates  
10064 Biochemistry studies - Proteins, peptides and amino acids  
10068 Biochemistry studies - Carbohydrates  
10506 Biophysics - Molecular properties and macromolecules  
15001 Blood - General and methods  
15002 Blood - Blood and lymph studies  
34502 Immunology - General and methods

BIOSYSTEMATIC CODES:

85715 Bovidae

**A SIMPLE AND EFFECTIVE ADDITIONAL STEP IN PURIFICATION OF BOVINE BLOOD  
SERUM FIBRONECTIN**

ABSTRACT: Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained Ig and other proteins, concentration of which constituted 48  $\pm$  5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained < 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

**4/9,K/2 (Item 1 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

06266345 PMID: 6649521

**[A simple and effective step in the purification of bovine blood  
fibronectin ]**

Prostoi i effektivnyi dopolnitel'nyi etap ochistki fibronektina syvorotki byka.

Zykova T A; Zlatopol'skii A D; Mazurov V I

Voprosy meditsinskoi khimii (USSR) Sep-Oct 1983, 29 (5) p114-7,

ISSN 0042-8809--Print Journal Code: 0416601

Publishing Model Print

Document type: English Abstract; Journal Article

Languages: RUSSIAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained immunoglobulins and other proteins, concentration of which constituted 48  $\pm$  5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more

effectively as compared with non- **fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained less than 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

Descriptors: \*Fibronectins--blood--BL; Animals; Cattle; Chromatography, Affinity--methods--MT; Collagen; Fibronectins--isolation and purification--IP; Osmolar Concentration; Sepharose--analogs and derivatives--AA

CAS Registry No.: 0 (Fibronectins); 9007-34-5 (Collagen); 9012-36-6 (Sepharose)

Record Date Created: 19840107

Record Date Completed: 19840107

**[A simple and effective step in the purification of bovine blood fibronectin ]**

Preparations of **fibronectin** from **bovine blood serum**, obtained by means of affinity chromatography on collagen-Sepharose, contained immunoglobulins and other proteins, concentration of which constituted 48 +/- 5%. Differential salting out of **fibronectin** and other non-**fibronectin** proteins, using 0.8-2.0 M ammonium sulfate at pH 5.0, demonstrated that **precipitation** of **fibronectin** occurred more effectively as compared with non-**fibronectin** proteins at all the salt concentrations studied. If 0.8 M or 1.0 M ammonium sulfate concentrations were used, the **fibronectin** preparations contained less than 10% of other proteins and **fibronectin** loss was about 20%. Salting out of **fibronectin** is an effective additional step of its purification.

? s s3 and purif?

327 S3

2431983 PURIF?

S5 105 S3 AND PURIF?

? s s5 and von(n)willebrand

105 S5

885803 VON

70180 WILLEBRAND

68687 VON(N)WILLEBRAND

S6 22 S5 AND VON(N)WILLEBRAND

? s s5 and coagulation

105 S5

380553 COAGULATION

S7 12 S5 AND COAGULATION

? t s7/6,k/1-12

**7/6,K/1 (Item 1 from file: 5)**

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

14475793 BIOSIS NO.: 199800270040

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-(N-(4-aminobutyl)-N-ethylamino)-2,3-dihydrophthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate**  
1998

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-(N-(4-aminobutyl)-N-ethylamino)-2,3...**

...ABSTRACT: novel and sensitive chemiluminescent assay is described to

quantitate the acyl transfer activities of blood **coagulation factor** XIIIa or liver transglutaminase using aminobutyl-N-ethylisoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. The method involved covalently linking aminobutyl-N-ethyl-isoluminol through its free...

...protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor** XIIIa. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

...ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor** XIIIa and transglutaminase activities with the chemiluminescent assay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor** XIII, or boiled enzymes, and by competitive inhibition with putrescine and 5'-(biotinamido) pentylamine. The enzymatic and kinetic properties of **factor** XIIIa and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... **factor** XIIIa

MISCELLANEOUS TERMS: blood **coagulation**

**7/6,K/2 (Item 2 from file: 5)**

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

09326998 BIOSIS NO.: 198936035889

PURIFICATION OF BLOOD COAGULATION FACTOR VIII BY PRECIPITATION WITH SULFATE POLYSACCHARIDES US PATENT-4789733. DECEMBER 6 1988

1988

PURIFICATION OF BLOOD COAGULATION FACTOR VIII BY PRECIPITATION WITH SULFATE POLYSACCHARIDES US PATENT-4789733. DECEMBER 6 1988

...REGISTRY NUMBERS: **FACTOR** VIII...

... **FACTOR** VIII...

... **FACTOR** VIII

DESCRIPTORS: USCL-530-383 FIBRINOGEN **FIBRONECTIN** SUPERNATANT TEMPERATURE

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: **FACTOR** VIII...

... **FACTOR** VIII...

... **FACTOR** VIII

**7/6,K/3 (Item 3 from file: 5)**

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

07700943 BIOSIS NO.: 198580009838

COAGULATION **PROTEINS SHOWING ABNORMAL ELECTROPHORETIC MOBILITY IN**

COMMERCIAL CONCENTRATES OF FACTOR -VIII AND PROTHROMBIN COMPLEX  
1984

COAGULATION PROTEINS SHOWING ABNORMAL ELECTROPHORETIC MOBILITY IN  
COMMERCIAL CONCENTRATES OF FACTOR -VIII AND PROTHROMBIN COMPLEX

ABSTRACT: Five commercial **factor** VIII (FVIII) concentrates and 3 prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, **fibronectin**, .alpha.2-antiplasmin (.alpha.2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunoelectrophoresis (CIE) and von Willebrand **factor** antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern with the absence or a decrease of larger forms and the presence of a fast-moving **precipitating** peak, suggesting degradation of the vWF:Ag in FVIII concentrates. The electrophoretic mobility of **fibronectin**, .alpha.2-AP and AT-III was normal. All PCC showed a more anodic mobility of **factor** IX. .alpha.2-AP also exhibited a different electrophoretic pattern to that of normal plasma...  
...of AT-III was also found in heparin-binding studies. The techniques used in the **purification** procedures are probably the mechanism responsible for the partial denaturing of these proteins.  
...REGISTRY NUMBERS: **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -IX...

... **FACTOR** -XIII...

... **FACTOR** -II...

... **FACTOR** -II

DESCRIPTORS: HUMAN HEMATOLOGIC-DRUG **FACTOR** -IX ALPHA-2 ANTIPLASMIN **FACTOR** -XIII **FACTOR** -II ANTITHROMBIN III **FIBRONECTIN**  
DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -VIII...

... **FACTOR** -IX...

... **FACTOR** -XIII...

... **FACTOR** -II...

... **FACTOR** -II

7/6,K/4 (Item 1 from file: 34)

DIALOG(R)File 34:(c) 2008 The Thomson Corp. All rts. reserv.

06697763 Genuine Article#: ZL472 Number of References: 23

Title: Enzymatic and kinetic properties of blood coagulation factor  
XIIIa and guinea pig liver transglutaminase utilizing



(6-[N-(4-aminobutyl)-N-ethylamino]-2,3-dihydrophthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate (ABSTRACT AVAILABLE)

Publication date: 19980100

**Title: Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3...**

...Abstract: novel and sensitive chemiluminescent assay is described to quantitate the acyl transfer activities of blood **coagulation factor XIIIa** or liver transglutaminase using aminobutyl-N-ethyl-isoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. Th a method involved covalently linking aminobutyl-N-ethyl-isoluminol through its...

...protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor XIIIa**. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

...ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor XIIIa** and transglutaminase activities with the chemiluminescent essay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor XIII**, or boiled enzymes, and by competitive inhibition with putrescine and 5'-(biotinamido) pentylamine. The enzymatic and kinetic properties of **factor XIIIa** and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

...Identifiers--TRANSAMIDATING ENZYMES; CHEMI-LUMINESCENT; ASSAY; **PURIFICATION**; PROTEIN; TISSUES; LUMINOL; SITE

7/6,K/5 (Item 1 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

0072901687 EMBASE No: 1985107103

Coagulation **proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex**  
December 1, 1984

Coagulation **proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex**

Five commercial **factor VIII** (FVIII) concentrates and three prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, **fibronectin**, alpha SUB 2-antiplasmin (alpha SUB 2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunoelectrophoresis (CIE) and von Willebrand **factor** antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern with the absence or a decrease of larger forms and the presence of a fast-moving **precipitating** peak, suggesting degradation of the vWF:Ag in FVIII concentrates. In contrast, the electrophoretic mobility of **fibronectin**,

alpha SUB 2-AP and AT-III was normal. All PCC showed a more anodic mobility of **factor** IX. alpha SUB 2-AP also exhibited a different electrophoretic pattern to that of normal...

...of AT-III was also found in heparin-binding studies. The techniques used in the **purification** procedures are probably the mechanism responsible for the partial denaturing of these proteins.

DRUG DESCRIPTORS:

\*blood clotting **factor** 8; \*blood clotting **factor** 8 concentrate; \*prothrombin; \*prothrombin complex

CAS REGISTRY NO.: 9001-27-8 (blood clotting **factor** 8); 37224-63-8 (prothrombin complex); 9001-26-7 (prothrombin)

7/6,K/6 (Item 1 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

11789238 PMID: 9608360

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3-dihydrophthalazine-1,4-dione, as a novel, specific and sensitive chemiluminescent substrate.**

Jan-Feb 1998

**Enzymatic and kinetic properties of blood coagulation factor XIIIa and guinea pig liver transglutaminase utilizing (6-[N-(4-aminobutyl)-N-ethylamino]-2,3...**

... novel and sensitive chemiluminescent assay is described to quantitate the acyl transfer activities of blood **coagulation factor** XIIIa or liver transglutaminase using aminobutyl-N-ethylisoluminol as acyl acceptor and N,N-dimethylcasein, human plasma fibrinogen or **fibronectin** as acyl donors. The method involved covalently linking aminobutyl-N-ethyl-isoluminol through its free...

... protein-bound glutamine resulting in an isopeptide bond; a reaction catalysed by both transglutaminase and **factor** XIIIa. The protein-bound aminobutyl-N-ethyl-isoluminol was separated from non-conjugated amine by **precipitation** with trichloroacetic acid. The protein-amine conjugate was dissolved in 500 mmol/L NaOH, oxidized...

... ammonium persulphate and light emission quantitated using a luminometer. Optimal conditions were established to detect **factor** XIIIa and transglutaminase activities with the chemiluminescent assay. Specificity was demonstrated by lack of activity in the presence of ethylenediamine tetra-acetic acid or unactivated **factor** XIII, or boiled enzymes, and by competitive inhibition with putrescine and 5'-(biotinamido) pentylamine. The enzymatic and kinetic properties of **factor** XIIIa and transglutaminase in utilizing aminobutyl-N-ethyl-isoluminol as an acyl acceptor substrate were comprehensively documented. The reaction could be carried out in either a **purified** system or a complex plasma or cell lysates milieu. The assay is sensitive, specific, and...

7/6,K/7 (Item 2 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08924152 PMID: 1858340

**[Production of a fibrinogen concentrate from small amounts of human**

**autologous blood plasma and its short-term characteristics]**

Poluchenie kontsentrata fibrinogena iz nebol'shikh kolichestv plazmy autogennoi krovi cheloveka i ego kratkaia kharakteristika.  
Jan-Feb 1991

... was developed for production of fibrinogen concentrate from small amounts of human autogenous blood using **precipitation** with polyethylene glycol and ammonium sulfate. Maximal yield of fibrinogen was obtained using polyethylene glycol...

... and 6,000 daltons at concentrations 7% and 4.5%, respectively. The fibrinogen preparations included **fibronectin**, inhibitors of proteinases, **factor** XIII of blood **coagulation**, plasminogen. Sigma-Aminocaproic acid and contrical should be added during bloodletting as well as into...

Descriptors: \*Blood; \*Fibrinogen--isolation and **purification** --IP; Electrophoresis, Polyacrylamide Gel; **Factor** XIII--chemistry--CH; Fibrinogen--analysis--AN; Fibronectins--analysis--AN; Humans; Plasminogen--analysis--AN; Polyethylene Glycols...

Chemical Name: Fibronectins; Polyethylene Glycols; Protease Inhibitors; Fibrinogen; Plasminogen; **Factor** XIII

**7/6,K/8 (Item 3 from file: 155)**

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06712389 PMID: 3922084

**The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.**

Mar 15 1985

**The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.**

To evaluate the role of **fibronectin** (Fn) in **factor** VIII (FVIII) and von Willebrand **factor** (vWf) cryoprecipitation, **factor** VIII procoagulant activity, **factor** VIII coagulant antigen, **factor** VIII-related antigen and von Willebrand ristocetin cofactor activity were measured in cryoprecipitate and cryosupernatant...

...antibodies behaved differently: although their cryoprecipitate contained normal fibrinogen levels, neither FVIII nor FvWf was **precipitated**. Experiments performed with Fn-depleted plasma to which **purified fibronectin** had been added, and samples of plasma with decreased Fn levels (0.01 to 0...

Descriptors: \*Blood **Coagulation** Factors--isolation and **purification** --IP; \* **Factor** VIII--isolation and **purification** --IP; \*Fibronectins --blood--BL; \*von Willebrand **Factor** --isolation and **purification** --IP; Freezing; Humans; **Precipitation**

Chemical Name: Blood **Coagulation** Factors; Fibronectins; von Willebrand **Factor**; **Factor** VIII

**7/6,K/9 (Item 4 from file: 155)**

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06630779 PMID: 6442908

**Coagulation proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex.**

1984

Coagulation **proteins showing abnormal electrophoretic mobility in commercial concentrates of factor VIII and prothrombin complex.**

Five commercial **factor VIII (FVIII)** concentrates and three prothrombin complex concentrates (PCC) were studied with reference to the qualitative evaluation of factors II, IX, **fibronectin**, alpha 2-antiplasmin (alpha 2-AP), antithrombin III (AT-III) and subunits A and S of FXIII by crossed-immunoelectrophoresis (CIE) and von Willebrand **factor** antigen (vWF:Ag) by radio-CIE. This latter protein had a different pattern with the absence or a decrease of larger forms and the presence of a fast-moving **precipitating** peak, suggesting degradation of the vWF:Ag in FVIII concentrates. In contrast, the electrophoretic mobility of **fibronectin**, alpha 2-AP and AT-III was normal. All PCC showed a more anodic mobility of **factor IX**. alpha 2-AP also exhibited a different electrophoretic pattern to that of normal plasma...

...of AT-III was also found in heparin-binding studies. The techniques used in the **purification** procedures are probably the mechanism responsible for the partial denaturing of these proteins.

Descriptors: \*Blood **Coagulation** Factors--analysis--AN; \* **Factor VIII** --analysis--AN; Antithrombin III--analysis--AN; Blood **Coagulation** Factors --isolation and **purification** --IP; Blood **Coagulation** Factors--standards --ST; Blood Protein Electrophoresis; Counterimmunoelectrophoresis; Drug Contamination; **Factor VIII**--isolation and **purification** --IP; **Factor VIII**--standards--ST; **Fibronectins**--analysis--AN; Humans; Protein Denaturation

Chemical Name: Blood **Coagulation** Factors; **Fibronectins**; prothrombin complex concentrates; Antithrombin III; **Factor VIII**

7/6,K/10 (Item 5 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06555871 PMID: 6437941

**Isolation of small molecular forms of Factor VIII/von Willebrand factor from plasma.**

1984

**Isolation of small molecular forms of Factor VIII/von Willebrand factor from plasma.**

Cryoprecipitated **factor VIII/von Willebrand factor (FVIII/vWF)**, freed of fibrinogen by clotting with calcium and Defibrase, was chromatographed on Sepharose...

... forms of FVIII/vWF comprised coprecipitated plasma proteins of similar molecular weights. The major contaminants, **fibronectin** and IgM, were removed by affinity chromatography on gelatin- and anti-IgM-agarose, respectively. Finally...

Descriptors: \*Blood **Coagulation** Factors--isolation and **purification** --IP; \* **Factor VIII**--isolation and **purification** --IP; \*von Willebrand **Factor** --isolation and **purification** --IP; Chromatography--methods--MT; Cold; Humans; Molecular Weight; **Precipitation**

Chemical Name: Blood **Coagulation** Factors; von Willebrand **Factor**; **Factor VIII**

7/6,K/11 (Item 6 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

06237133 PMID: 6415800

[Plasma fibronectin ]

La fibronectine plasmatique.

Jun 1983

[Plasma fibronectin ]

**Fibronectin** (FN) is a glycoprotein (disulfite-bonded dimer of 200 to 220 Kd subunits) found in...

... like collagen, proteoglycans... FN fundamentally forms molecular complexes with collagen, fibrinogen or fibrin, heparin, activated **factor** XIII, bacteria, cellular membranes..., these various proteins binding with now well known functional "domains" on...

...also interacts with hemostatic and fibrinolytic systems, as component of the subendothelium (secreted, like Willbrand **factor** , by endothelial cells) and of platelet alpha-granules released by stimulated platelets. FN could then provoke platelet spreading on the subendothelium surface after collagen-platelet adhesion, triggered by Willebrand **factor** , has happened. FN is a part of the fibrinous clot. It participates in anchorage of...

; Animals; Blood **Coagulation** ; Cell Adhesion; Cell Movement; Cell Transformation, Viral; Chemistry; Chromatography, Affinity; Collagen--metabolism--ME; **Factor** VIII--metabolism--ME; Fibrin--metabolism--ME; Fibrinogen--metabolism--ME; Fibroblasts--metabolism--ME; Fibronectins--analysis--AN; Fibronectins--isolation and **purification** --IP; Heparin--blood--BL; Humans; Molecular Weight; Opsonin Proteins; Peptide Hydrolases--pharmacology--PD; **Precipitation** ; Rats; Wound Healing

Chemical Name: Fibronectins; Opsonin Proteins; cryoprecipitate coagulum; **Factor** VIII; Fibrin; Fibrinogen; Heparin; Collagen; Peptide Hydrolases

7/6,K/12 (Item 1 from file: 357)

DIALOG(R)File 357:(c) 2008 The Thomson Corp. All rts. reserv.

0411605 DBR Accession No.: 2006-25101

**Recombinant production of proteins comprises subjecting a suspension of the cells to a non-physiologically increased concentration of at least one ionic substance, e.g. amino acid, prior to harvest of protein - recombinant protein production via plasmid expression in cell culture for disease therapy** 2006

...ABSTRACT: FIX, FIXa, FVII, FVIIa, FVIII, FVIIIa, FXI, FXIa, FXII, FXIIa, FXIII and FXIIIa, von Willebrand **factor** , transport proteins including albumin, transferrin, ceruloplasmin, haptoglobin, hemoglobin and hemopexin, protease inhibitors including beta-antithrombin, alpha-antithrombin, alpha2-macroglobulin, C1-inhibitor, tissue is **factor** pathway inhibitor (TFPI), heparin cofactor II, protein C inhibitor (PAI-3), Protein C and Protein...

... reactive protein and other proteins including histidine-rich glycoprotein, mannan binding lectin, C4-binding protein, **fibronectin** , GC-globulin, plasminogen, blood factors such as erythropoietin, Interferon, tumor factors, tPA, gCSF, or their derivatives and muteins, more preferably the plasma protein is a human **factor** VIII or a human

FIX protein or its mutein, even more preferably is a B-domain deleted **factor** VIII protein, most preferably is the **factor** VIII mutein having a sequence comprising 1459 amino acids (SEQ ID NOS: 4 or 6...

... magnetic fields and ultra filtration. The isolation of the protein from the medium and its **purification** is effected by using at least one technique selected from immuno-affinity chromatography, affinity chromatography, protein **precipitation**, buffer exchanges, ionic exchange chromatography, hydrophobic interaction chromatography, mixed mode hydrophobic/ion exchange chromatography media...

... chromatography, carbohydrate affinity like lectin or heparin affinity chromatography, size-exclusion chromatography, electrophoresis, dialysis, different **precipitation** agents such as polyethylene glycol, ammonium sulphate, ethanol, hydroxy apatite adsorption, filter membrane adsorption, ligands coupled to magnetic particles etc. The carrier used for the chromatography **purification**, is selected from resins, particles, beads, membranes, hollow fiber or similar. The isolation of the...

... ultra filtration. The method is performed under sterile conditions, where the medium and/or the **purified** protein is subjected to a virus inactivation and/or removal step, and/or where the...

... filtrate of the micro filtration system. Preferred Pharmaceutical Composition: The pharmaceutical composition comprises a blood **coagulation factor**, preferably a FVIII or FIX protein and is for treatment of hemophiliacs. ACTIVITY - Hemostatic. No...

DESCRIPTORS: recombinant fibrinogen protein, prothrombin, **Factor** -X, **Factor** -IX, **Factor** -VII, **Factor** -VIII, **Factor** -XI, **Factor** -XII, **Factor** -XIII, von Willebrand **factor**, transport protein prep., vector-mediated gene transfer expression in host cell, immortalized mammal cell continuous...

? s s6 and pH

22 S6

4138455 PH

S8 4 S6 AND PH

? t s8/6,k/1-4

**8/6,K/1 (Item 1 from file: 155)**

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

13892079 PMID: 12186399

**Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.**

Aug 2002

... aggregation caused by all agonists tested except ristocetin. Further, both inhibited human platelet adhesion to **von Willebrand factor**, fibrinogen, **fibronectin** and subendothelial matrix with similar potency. Fibrinogen binding to washed platelets was dose-dependently inhibited...

... 700 +/- 3,000 for YM337 and 76,000 +/- 5,400 for abciximab. GPIIb/IIIa was **precipitated** from the solubilized fraction of platelets by both agents. In contrast, integrin alphavbeta3 was **precipitated** from the solubilized fraction of human umbilical vein endothelial cells by abciximab but not by YM337. Fibrinogen binding to **purified** GPIIb/IIIa was

dose-dependently inhibited by both agents. In contrast, vitronectin binding to **purified** integrin alphavbeta3 was dose-dependently inhibited by abciximab but not by YM337, supporting the idea...

...; Immunoglobulin Fab Fragments--metabolism--ME; Platelet Adhesiveness; Platelet Aggregation--drug effects--DE; Platelet Aggregation--physiology--**pH** ; Platelet Aggregation Inhibitors--metabolism--ME; Platelet Glycoprotein GPIIb-IIIa Complex--antagonists and inhibitors--AI; Protein Binding--drug effects--DE; Protein Binding--physiology-- **pH**

8/6,K/2 (Item 2 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08600770 PMID: 2119525

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

Jun 28 1990

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

A high yield, intermediate purity **factor VIII** concentrate derived from heparinized plasma has been developed which can be heat-treated at...

... which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate** was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibronectin** , a **factor VIII**-rich supernatant can be recovered which contains greater than 500 units of VIII:C...

...at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72...

...9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose ( **pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80...

... v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: **\*Factor VIII**--isolation and **purification** --IP; **\* von Willebrand Factor** --isolation and **purification** --IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis --AN; Plasma--drug effects--DE; **Precipitation** ; Solubility; Water --analysis--AN

Chemical Name: Macromolecular Substances; **von Willebrand Factor** ; Water; **Factor VIII**; Heparin

8/6,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

08057133 PMID: 2495039

**Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.**

Mar 1989

**Some characteristics of aggregates of IgG and plasma proteins in**

**heat-treated factor VIII concentrates.**

Eight batches of commercial heat-treated and one untreated **factor VIII** concentrate from 6 producers were analyzed for their content of IgG, IgG subclasses, IgG...

... for anticomplement activity. Methods used were thin-layer gel filtration, immuno-gel filtration, spot immuno-**precipitate** assay in a double antibody version and an agarose plate haemolysis inhibition assay of complement...

... compared to normal serum and intravenous immunoglobulin, one to four of the following plasma proteins; **fibronectin**, fibrinogen, **von Willebrand factor** antigen, Clq, albumin and IgA. Three batches from two producers had high anticomplementary activity, presumably...

Descriptors: \*Blood Proteins--isolation and **purification** --IP; \* **Factor VIII**--analysis--AN; \*Heat; \*Immunoglobulin G--isolation and **purification** --IP...; Thin Layer; Complement System Proteins--immunology--IM; Humans; Immunoglobulin G--classification--CL; Immunoglobulin G--physiology-- **pH** ; Macromolecular Substances; Precipitin Tests

Chemical Name: Blood Proteins; Immunoglobulin G; Macromolecular Substances; **Factor VIII**; Complement System Proteins

**8/6,K/4 (Item 1 from file: 357)**

DIALOG(R)File 357:(c) 2008 The Thomson Corp. All rts. reserv.

0411605 DBR Accession No.: 2006-25101

**Recombinant production of proteins comprises subjecting a suspension of the cells to a non-physiologically increased concentration of at least one ionic substance, e.g. amino acid, prior to harvest of protein - recombinant protein production via plasmid expression in cell culture for disease therapy 2006**

...ABSTRACT: FX, Fa, FIX, FIXa, FVII, FVIIa, FVIII, FVIIIa, FXI, FXIa, FXII, FXIIa, FXIII and FXIIIa, **von Willebrand factor**, transport proteins including albumin, transferrin, ceruloplasmin, haptoglobin, hemoglobin and hemopexin, protease inhibitors including beta-antithrombin, alpha-antithrombin, alpha2-macroglobulin, C1-inhibitor, tissue is **factor** pathway inhibitor (TFPI), heparin cofactor II, protein C inhibitor (PAI-3), Protein C and Protein...

... reactive protein and other proteins including histidine-rich glycoprotein, mannan binding lectin, C4-binding protein, **fibronectin**, GC-globulin, plasminogen, blood factors such as erythropoietin, Interferon, tumor factors, tPA, gCSF, or their derivatives and muteins, more preferably the plasma protein is a human **factor VIII** or a human FIX protein or its mutein, even more preferably is a B-domain deleted **factor VIII** protein, most preferably is the **factor VIII** mutein having a sequence comprising 1459 amino acids (SEQ ID NOS: 4 or 6...

... of non-ionic detergents. The release composition further comprises a buffering substance to stabilize the **pH**, preferably the buffering substance is selected from Goods buffer substances, including HEPES, MES, TRIS, etc. The **pH** of the cell suspension when subjected to the increased concentration of the at least one...

... magnetic fields and ultra filtration. The isolation of the protein from



the medium and its **purification** is effected by using at least one technique selected from immuno-affinity chromatography, affinity chromatography, protein **precipitation**, buffer exchanges, ionic exchange chromatography, hydrophobic interaction chromatography, mixed mode hydrophobic/ion exchange chromatography media...

... chromatography, carbohydrate affinity like lectin or heparin affinity chromatography, size-exclusion chromatography, electrophoresis, dialysis, different **precipitation** agents such as polyethylene glycol, ammonium sulphate, ethanol, hydroxy apatite adsorption, filter membrane adsorption, ligands coupled to magnetic particles etc. The carrier used for the chromatography **purification**, is selected from resins, particles, beads, membranes, hollow fiber or similar. The isolation of the...

... ultra filtration. The method is performed under sterile conditions, where the medium and/or the **purified** protein is subjected to a virus inactivation and/or removal step, and/or where the...

... of the micro filtration system. Preferred Pharmaceutical Composition: The pharmaceutical composition comprises a blood coagulation **factor**, preferably a FVIII or FIX protein and is for treatment of hemophiliacs. ACTIVITY - Hemostatic. No...

DESCRIPTORS: recombinant fibrinogen protein, prothrombin, **Factor -X**, **Factor -IX**, **Factor -VII**, **Factor -VIII**, **Factor -XI**, **Factor -XII**, **Factor -XIII**, **von Willebrand factor**, transport protein prep., vector-mediated gene transfer expression in host cell, immortalized mammal cell continuous...

? t s8/9,k/2

**8/9,K/2 (Item 2 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

08600770 PMID: 2119525

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

Palmer D S; Ganz P R; Perkins H; Rosborough D; Rock G

Ottawa Centre, Canadian Red Cross, Blood Transfusion Service, Ontario.

Thrombosis and haemostasis (GERMANY, WEST) Jun 28 1990, 63 (3) p392-402, ISSN 0340-6245--Print Journal Code: 7608063

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

A high yield, intermediate purity **factor** VIII concentrate derived from heparinized plasma has been developed which can be heat-treated at 60 degrees C, 68 degrees C or 80 degrees C/72 h to permit inactivation of viral contaminants which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate**0 was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibronectin**, a **factor** VIII-rich supernatant can be recovered which contains greater than 500 units of VIII:C per liter of starting plasma (Method I product) at a purity of 1.5 U/mg protein.

Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72 h without a significant loss of VIII:C activity. However, at 68 degrees C or 80 degrees C/72 h, temperatures now reported to be more effective in viral inactivation, the recoveries were reduced to 68 and 33% respectively. Significantly improved recoveries after heat-treatment (HT) at 68 degrees C or 80 degrees C/72 h were achieved if the 8 degrees C supernatant product was prepared by a modified procedure (Method II). This further reduces the fibrinogen content of the product while maintaining VIII:C yields greater than 500 U/l at a purity of 1.9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (**pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80 degrees C/72 h, the VIII:C recoveries of Method II product were 88-100%, 79-84% and 80-83% of pre-HT levels respectively. The yield of VIII:C was greater than 400 U/l at a purity of 1.6-1.4 U/mg at 1-2% (w/v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: **\*Factor VIII**--isolation and **purification** --IP; **\* von Willebrand Factor** --isolation and **purification** --IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis --AN; Plasma--drug effects--DE; **Precipitation** ; Solubility; Water --analysis--AN

CAS Registry No.: 0 (Macromolecular Substances); 0 (von Willebrand Factor); 7732-18-5 (Water); 9001-27-8 (Factor VIII); 9005-49-6 (Heparin)

Record Date Created: 19901019

Record Date Completed: 19901019

**Development of a heat-treated factor VIII/ von Willebrand factor concentrate prepared from heparinized plasma.**

A high yield, intermediate purity **factor VIII** concentrate derived from heparinized plasma has been developed which can be heat-treated at...

... which may be present. After cold reprecipitation of the heparinized cryoprecipitate (CRC), the resolubilized CRC **precipitate** was adjusted to 25-30 mg/ml protein and **pH** 6.35 +/- 0.1 and incubated for 1 h at 8 degrees C. After centrifugation to remove the **precipitated** fibrinogen and **fibronectin** , a **factor VIII**-rich supernatant can be recovered which contains greater than 500 units of VIII:C...

...at a purity of 1.5 U/mg protein. Adjusted to 50 mM glycine and **pH** 6.8, the product can be lyophilized and heat-treated at 60 degrees C/72...

...9 U/mg. When adjusted to 50 mM glycine and 1-2% (w/v) sucrose (**pH** 6.8), lyophilized and heat treated at 60 degrees C, 68 degrees C or 80...

... v) sucrose even after the severe heat-treatment at 80 degrees C. In addition, the **von Willebrand factor** multimers are similar in size and triplet pattern to those observed in routine cryoprecipitate preparations.

Descriptors: **\*Factor VIII**--isolation and **purification** --IP; **\* von Willebrand Factor** --isolation and **purification** --IP; Cold; Freeze Drying; Heat; Heparin; Humans; Macromolecular Substances; Plasma--analysis --AN; Plasma--drug effects--DE; **Precipitation** ; Solubility; Water --analysis--AN

Chemical Name: Macromolecular Substances; **von Willebrand Factor** ; Water; **Factor VIII**; Heparin

? logoff y

23jan08 11:05:20 User276653 Session D136.2

|         |                |       |           |                     |
|---------|----------------|-------|-----------|---------------------|
|         | \$7.84         | 1.306 | DialUnits | File5               |
|         | \$2.30         | 1     | Type(s)   | in Format 9         |
|         | \$0.54         | 3     | Type(s)   | in Format 95 (KWIC) |
|         | \$2.84         | 4     | Types     |                     |
| \$10.68 | Estimated cost |       | File5     |                     |
|         | \$0.80         | 0.130 | DialUnits | File24              |
| \$0.80  | Estimated cost |       | File24    |                     |
|         | \$0.24         | 0.039 | DialUnits | File28              |
| \$0.24  | Estimated cost |       | File28    |                     |
|         | \$17.94        | 0.674 | DialUnits | File34              |
|         | \$0.46         | 1     | Type(s)   | in Format 95 (KWIC) |
|         | \$0.46         | 1     | Types     |                     |
| \$18.40 | Estimated cost |       | File34    |                     |
|         | \$0.29         | 0.071 | DialUnits | File35              |
| \$0.29  | Estimated cost |       | File35    |                     |
|         | \$0.26         | 0.037 | DialUnits | File40              |
| \$0.26  | Estimated cost |       | File40    |                     |
|         | \$0.37         | 0.059 | DialUnits | File41              |
| \$0.37  | Estimated cost |       | File41    |                     |
|         | \$0.68         | 0.135 | DialUnits | File45              |
| \$0.68  | Estimated cost |       | File45    |                     |
|         | \$0.73         | 0.158 | DialUnits | File50              |
| \$0.73  | Estimated cost |       | File50    |                     |
|         | \$0.19         | 0.045 | DialUnits | File65              |
| \$0.19  | Estimated cost |       | File65    |                     |
|         | \$1.90         | 0.189 | DialUnits | File71              |
| \$1.90  | Estimated cost |       | File71    |                     |
|         | \$11.34        | 0.883 | DialUnits | File73              |
|         | \$0.42         | 1     | Type(s)   | in Format 95 (KWIC) |
|         | \$0.42         | 1     | Types     |                     |
| \$11.76 | Estimated cost |       | File73    |                     |
|         | \$0.18         | 0.042 | DialUnits | File91              |
| \$0.18  | Estimated cost |       | File91    |                     |
|         | \$0.19         | 0.045 | DialUnits | File98              |
| \$0.19  | Estimated cost |       | File98    |                     |
|         | \$0.13         | 0.023 | DialUnits | File110             |
| \$0.13  | Estimated cost |       | File110   |                     |
|         | \$0.59         | 0.104 | DialUnits | File135             |
| \$0.59  | Estimated cost |       | File135   |                     |
|         | \$0.35         | 0.056 | DialUnits | File136             |
| \$0.35  | Estimated cost |       | File136   |                     |
|         | \$0.11         | 0.037 | DialUnits | File143             |
| \$0.11  | Estimated cost |       | File143   |                     |
|         | \$2.54         | 0.513 | DialUnits | File144             |
| \$2.54  | Estimated cost |       | File144   |                     |
|         | \$3.28         | 0.965 | DialUnits | File155             |
|         | \$0.44         | 2     | Type(s)   | in Format 9         |
|         | \$0.45         | 9     | Type(s)   | in Format 95 (KWIC) |
|         | \$0.89         | 11    | Types     |                     |
| \$4.17  | Estimated cost |       | File155   |                     |
|         | \$0.15         | 0.042 | DialUnits | File164             |
| \$0.15  | Estimated cost |       | File164   |                     |
|         | \$0.58         | 0.045 | DialUnits | File172             |
| \$0.58  | Estimated cost |       | File172   |                     |
|         | \$0.38         | 0.062 | DialUnits | File185             |
| \$0.38  | Estimated cost |       | File185   |                     |
|         | \$3.14         | 0.124 | DialUnits | File357             |

\$0.64 2 Type(s) in Format 95 (KWIC)  
\$0.64 2 Types  
\$3.78 Estimated cost File357  
      \$0.12 0.034 DialUnits File369  
\$0.12 Estimated cost File369  
      \$0.14 0.039 DialUnits File370  
\$0.14 Estimated cost File370  
      \$0.00 0.054 DialUnits File391  
\$0.00 Estimated cost File391  
      \$2.93 0.110 DialUnits File434  
\$2.93 Estimated cost File434  
      \$0.23 0.037 DialUnits File467  
\$0.23 Estimated cost File467  
      OneSearch, 29 files, 6.058 DialUnits FileOS  
\$2.40 TELNET  
\$65.27 Estimated cost this search  
\$65.30 Estimated total session cost 6.325 DialUnits

Logoff: level 05.20.01 D 11:05:20

You are now logged off